Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

CareDx Q3 revenue beats estimates on testing services growth; raises FY2026 outlook

By Reuters News


Overview

  • U.S. precision diagnostics firm's Q3 revenue rose 39%, beating analyst expectations

  • Q3 adjusted EBITDA nearly doubled yr/yr to $30 mln

  • Company raised 2026 revenue and adjusted EBITDA guidance


Outlook

  • CareDx raises 2026 revenue guidance to $520 mln-$530 mln

  • Company now expects 2026 adjusted EBITDA of $90 mln-$100 mln

  • CareDx plans a Q1 2027 commercial launch of AlloHeme and broader HistoMap Kidney availability in 2027


Result Drivers

  • TESTING SERVICES - Revenue rose 65% to $119 mln, including $12 mln from Specialty Oncology and $15 mln of prior-period revenue

  • PHARMACY SERVICES - Patient and Digital Solutions revenue rose 31%, mainly due to growth in CareDx Pharmacy services

  • NAVERIS ACQUISITION - Specialty Oncology contributed $12 mln to Testing Services revenue following the acquisition of Naveris


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$139 mln

$120.61 mln (7 Analysts)

Q3 Net Income

$19 mln

Q3 Adjusted EBITDA

$30 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for CareDx, Inc. is $61.00, about 15.4% below its October 28 closing price of $72.13

  • The stock recently traded at 58 times the next 12-month earnings vs. a P/E of 30 three months ago


Reuters Recommended Reads

  • Oct 29 - Alnylam Pharmaceuticals Q3 revenue rises on AMVUTTRA demand

  • Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment

  • Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.